《bioRxiv,4月12日,Immuno-informatics Characterization SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope based Multivalent Peptide Vaccine》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-04-13
  • Immuno-informatics Characterization SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope based Multivalent Peptide Vaccine

    Saba Ismail, Sajjad Ahmad, Syed Sikander Azam

    doi: https://doi.org/10.1101/2020.04.05.026005

    Abstract

    The COVID-19 pandemic caused by SARS-CoV-2 is a public-health emergency of international concern and thus calling for the development of safe and effective therapeutics and prophylactics particularly a vaccine to protect against the infection. SARS-CoV-2 spike glycoprotein is an attractive candidate for vaccine, antibodies and inhibitor development because of many roles it plays in attachment, fusion and entry into the host cell. In this study, we characterized the SARS-CoV-2 spike glycoprotein by immune-informatics techniques to put forward potential B and T cell epitopes, followed by the use of epitopes in construction of a multi-epitope peptide vaccine construct (MEPVC). The MEPVC revealed robust host immune system simulation with high production of immunoglobulins, cytokines and interleukins. Stable conformation of the MEPVC with a representative innate immune TLR3 receptor was observed involving strong hydrophobic and hydrophilic chemical interactions, along with enhanced contribution from salt-bridges towards inter-molecular stability. Molecular dynamics simulation in solution aided further in interpreting strong affinity of the MEPVC for TLR3. This stability is the attribute of several vital residues from both TLR3 and MEPVC as shown by radial distribution function (RDF) and a novel analytical tool axial frequency distribution (AFD). Comprehensive binding free energies estimation was provided at the end that concluded major domination by electrostatic and minor from van der Waals. Summing all, the designed MEPVC has tremendous potential of providing protective immunity against COVID-19 and thus has the potential to be considered in experimental studies.

  • 原文来源:https://www.biorxiv.org/content/10.1101/2020.04.05.026005v1
相关报告
  • 《BioRxiv,2月27日,Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-28
    • Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2 Lin Li, Ting Sun, YuFei He, Wendong Li, Yubo Fan, Jing Zhang doi: https://doi.org/10.1101/2020.02.25.965434 Abstract The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected thousands of people with a large number of deaths across 26 countries. The sudden appearance of the virus leads to the limited existing therapies for SARS-CoV-2. Therefore, vaccines and antiviral medicines are in desperate need. This study took immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.
  • 《4月12日_通过免疫信息学表征SARS-CoV-2刺突蛋白,用于基于抗原表位的多价肽疫苗的优化》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-14
    • 1.时间:2020年4月12日 2.机构或团队:巴基斯坦真纳大学 3.事件概要: 巴基斯坦真纳大学国家生物信息学中心的科研人员在bioRxiv预印本平台发表题为“Immuno-informatics Characterization SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope based Multivalent Peptide Vaccine”的文章。 文章指出,SARS-CoV-2刺突糖蛋白是疫苗、抗体和抑制剂开发的候选靶标,因为它在附着、融合和进入宿主细胞中发挥了许多作用。该研究中,研究人员通过免疫信息学技术表征了SARS-CoV-2刺突糖蛋白,提出了潜在的B和T细胞表位,然后利用表位构建多表位肽疫苗结构体(multi-epitope peptide vaccine construct , MEPVC)。MEPVC显示了强大的宿主免疫系统模拟与高产量的免疫球蛋白、细胞因子和白介素。观察到具有代表性的天然免疫TLR3受体的MEPVC稳定构象,涉及强疏水和亲水化学相互作用,以及盐桥对分子间稳定性的增强。溶液中的分子动力学模拟进一步解释了MEPVC对TLR3的强亲和力。如径向分布函数和新型分析工具轴向频率分布所示,这种稳定性是TLR3和MEPVC都含有一些重要残留物的属性。最后提供了综合的结合自由能估计值,得出静电的主要作用和范德华力的次要作用的结论。总而言之,设计的MEPVC具有针对COVID-19提供免疫保护的巨大潜力,因此在实验研究中需要得到更多关注。 *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用。 4.附件: 原文链接:https://www.biorxiv.org/content/10.1101/2020.04.05.026005v1